A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

PHASE2TerminatedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

March 11, 2009

Primary Completion Date

June 21, 2010

Study Completion Date

June 21, 2010

Conditions
Depressive Disorder
Interventions
DRUG

orvepitant

neurokinin-1 antagonist

OTHER

Placebo

Placebo to match orvepitant 30 mg and 60 mg

Trial Locations (32)

11235

GSK Investigational Site, Brooklyn

18049

GSK Investigational Site, Emmaus

19131

GSK Investigational Site, Philadelphia

19139

GSK Investigational Site, Philadelphia

20852

GSK Investigational Site, Rockville

22903

GSK Investigational Site, Charlottesville

29201

GSK Investigational Site, Columbia

32216

GSK Investigational Site, Jacksonville

32789

GSK Investigational Site, Winter Park

32806

GSK Investigational Site, Orlando

44125

GSK Investigational Site, Garfield Heights

45408

GSK Investigational Site, Dayton

53226

GSK Investigational Site, Milwaukee

62711

GSK Investigational Site, Springfield

63301

GSK Investigational Site, Saint Charles

72223

GSK Investigational Site, Little Rock

75231

GSK Investigational Site, Dallas

78756

GSK Investigational Site, Austin

80239

GSK Investigational Site, Denver

85020

GSK Investigational Site, Phoenix

92868

GSK Investigational Site, Orange

97210

GSK Investigational Site, Portland

97301

GSK Investigational Site, Salem

06360

GSK Investigational Site, Norwich

02190

GSK Investigational Site, Weymouth

08046

GSK Investigational Site, Willingboro

78229-3815

GSK Investigational Site, San Antonio

V2A 4M4

GSK Investigational Site, Penticton

E1V 6X3

GSK Investigational Site, Miramichi

B1S 2E8

GSK Investigational Site, Sydney

L5M 4N4

GSK Investigational Site, Mississauga

J9A 1K7

GSK Investigational Site, Gatineau

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY